Overview
Multicentric carpo-tarsal osteolysis with or without nephropathy (also known as multicentric osteolysis, nodulosis, and arthropathy, or MONA; idiopathic multicentric osteolysis; or hereditary multicentric osteolysis) is a rare skeletal disorder characterized by progressive destruction (osteolysis) of the carpal bones (wrist) and tarsal bones (ankle), often beginning in early childhood. The condition primarily affects the musculoskeletal system, leading to pain, swelling, and progressive loss of bone in the hands and feet, which can result in significant functional impairment and deformity. Joint contractures, osteoporosis, and subcutaneous nodules may also develop. In many patients, the disease is accompanied by a progressive nephropathy (kidney disease) that can lead to proteinuria and, in severe cases, end-stage renal failure. The condition is caused by mutations in the MAFB gene, which encodes a transcription factor involved in bone and kidney development. The skeletal manifestations typically present in early childhood, with wrist and ankle swelling being among the first signs noticed by families. Radiographic imaging reveals progressive osteolysis of the carpal and tarsal bones, and in some cases, other bones may also be affected. Kidney involvement varies in severity and may not be present in all affected individuals, hence the designation 'with or without nephropathy.' There is currently no cure for multicentric carpo-tarsal osteolysis. Treatment is primarily supportive and symptomatic, focusing on pain management, physical therapy to maintain joint function, orthopedic interventions for skeletal deformities, and nephrology care for those with kidney involvement. Renal transplantation may be necessary in patients who progress to end-stage kidney disease. Regular monitoring of kidney function is recommended for all affected individuals. Bisphosphonates and anti-inflammatory medications have been tried with variable results.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Multicentric carpo-tarsal osteolysis with or without nephropathy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Multicentric carpo-tarsal osteolysis with or without nephropathy at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Multicentric carpo-tarsal osteolysis with or without nephropathy.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Multicentric carpo-tarsal osteolysis with or without nephropathy.
Community
No community posts yet. Be the first to share your experience with Multicentric carpo-tarsal osteolysis with or without nephropathy.
Start the conversation →Latest news about Multicentric carpo-tarsal osteolysis with or without nephropathy
No recent news articles for Multicentric carpo-tarsal osteolysis with or without nephropathy.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Multicentric carpo-tarsal osteolysis with or without nephropathy
What is Multicentric carpo-tarsal osteolysis with or without nephropathy?
Multicentric carpo-tarsal osteolysis with or without nephropathy (also known as multicentric osteolysis, nodulosis, and arthropathy, or MONA; idiopathic multicentric osteolysis; or hereditary multicentric osteolysis) is a rare skeletal disorder characterized by progressive destruction (osteolysis) of the carpal bones (wrist) and tarsal bones (ankle), often beginning in early childhood. The condition primarily affects the musculoskeletal system, leading to pain, swelling, and progressive loss of bone in the hands and feet, which can result in significant functional impairment and deformity. Joi
How is Multicentric carpo-tarsal osteolysis with or without nephropathy inherited?
Multicentric carpo-tarsal osteolysis with or without nephropathy follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Multicentric carpo-tarsal osteolysis with or without nephropathy typically begin?
Typical onset of Multicentric carpo-tarsal osteolysis with or without nephropathy is childhood. Age of onset can vary across affected individuals.